![Bernie Treidl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bernie Treidl
Directeur/Membre du Conseil chez Seraxis Holdings, Inc.
Postes actifs de Bernie Treidl
Sociétés | Poste | Début | Fin |
---|---|---|---|
ChemGen Corp.
![]() ChemGen Corp. BiotechnologyHealth Technology Part of Elanco Animal Health, Inc., ChemGen Corp. develops feed enzyme products that improve the efficiency of poultry, egg, and meat production. The company is based in Gaithersburg, MD. ChemGen was acquired by Elanco Animal Health, Inc. on February 17, 2012 for $206.90 million. | Corporate Officer/Principal | - | - |
Seraxis Pte Ltd.
![]() Seraxis Pte Ltd. BiotechnologyHealth Technology Seraxis Pte Ltd. provides biotechnology services. It offers a cure for insulin-dependent diabetes by replacing the lost insulin producing pancreatic cells with lab-grown cells, packaged within a device to protect the cells from immune rejection. The company was founded by William L. Rust in March 2013 and is headquartered in Singapore. | Directeur/Membre du Conseil | - | - |
Seraxis Holdings, Inc.
![]() Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Directeur/Membre du Conseil | - | - |
Seraxis, Inc.
![]() Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Bernie Treidl
Statistiques
Internationale
Etats-Unis | 4 |
Singapour | 2 |
Opérationnelle
Director/Board Member | 3 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 4 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
ChemGen Corp.
![]() ChemGen Corp. BiotechnologyHealth Technology Part of Elanco Animal Health, Inc., ChemGen Corp. develops feed enzyme products that improve the efficiency of poultry, egg, and meat production. The company is based in Gaithersburg, MD. ChemGen was acquired by Elanco Animal Health, Inc. on February 17, 2012 for $206.90 million. | Health Technology |
Seraxis Pte Ltd.
![]() Seraxis Pte Ltd. BiotechnologyHealth Technology Seraxis Pte Ltd. provides biotechnology services. It offers a cure for insulin-dependent diabetes by replacing the lost insulin producing pancreatic cells with lab-grown cells, packaged within a device to protect the cells from immune rejection. The company was founded by William L. Rust in March 2013 and is headquartered in Singapore. | Health Technology |
Seraxis Holdings, Inc.
![]() Seraxis Holdings, Inc. Financial ConglomeratesFinance Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust. | Finance |
Seraxis, Inc.
![]() Seraxis, Inc. Pharmaceuticals: MajorHealth Technology Part of Seraxis Pte Ltd., Seraxis, Inc. is a biotechnology company that specializes in developing a proprietary human stem cell line, sr1423, and manufacturing process to generate pancreatic islets that mimic native islets in purity and potency. The company is based in Germantown, MD. The company has also developed the seragraft device and other tools to enable survival and function of the islet replacement therapy in immunocompetent hosts. Seraxis aims to be the first to provide diabetics a clinical solution for glucose control and complete autonomy from insulin injections. The company was founded in 2013 by William L. Rust, who has been the CEO since 2013. | Health Technology |
- Bourse
- Insiders
- Bernie Treidl
- Expérience